Whitehawk Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Whitehawk Therapeutics Inc WHWK.OQ reported quarterly adjusted earnings of $1.83​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -68 cents. The mean expectation of three analysts for the quarter was for a loss of 46 cents per share. Wall Street expected results to range from -80 cents to -23 cents per share.

• Revenue rose 33.5% to $7.15 million from a year ago; analysts expected zero.

• Whitehawk Therapeutics Inc's reported EPS for the quarter was $1.83​.

• The company reported quarterly net income of $73.02 million.

• Whitehawk Therapeutics Inc shares had fallen by 8.4% this quarter and lost 48.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "hold"

• Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $2.00

This summary was machine generated from LSEG data May 8 at 10:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)